AstraZeneca

AltheRx raises $15M, names Jim Bennethum CEO, appoints new board of directors

Monday, May 6, 2013 10:41 AM

AltheRx Pharmaceuticals, a privately-held clinical development company, announced a restructuring that includes a $15 million financing, the appointment of Jim Bennethum as CEO, and the appointment of a new board of directors.

More... »

BIND Therapeutics, AstraZeneca ink cancer nanomedicine agreement

Monday, April 22, 2013 03:17 PM

BIND Therapeutics, a clinical-stage biopharmaceutical company, and AstraZeneca have entered into a strategic collaboration to develop and commercialize an Accurin, a targeted and programmable cancer nanomedicine from BIND's medicinal nanoengineering platform, based on a molecularly targeted kinase inhibitor developed and owned by AstraZeneca.

More... »

Horizon Discovery, AstraZeneca collaborate on oncology drug discovery

Monday, April 22, 2013 01:54 PM

Horizon Discovery, a provider of research tools to support translational genomics research, and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon's first-in-class kinase target program, HD-001, as a means of developing novel therapies for multiple cancer types.

More... »

AstraZeneca touts top-line results from OSKIRA-1 phase III study of fostamatinib in RA

Friday, April 5, 2013 12:33 PM

AstraZeneca released top-line results of OSKIRA-1, a phase III study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA). OSKIRA-1 had two primary endpoints: assessing signs and symptoms of RA as measured by ACR20 response rates, and an X-ray endpoint known as mTSS (modified Total Sharp Score).

More... »

MedImmune aquires Alphacore Pharma

Wednesday, April 3, 2013 02:20 PM

MedImmune, AstraZeneca’s global biologics R&D arm, has acquired AlphaCore Pharma, an Ann Arbor, Mich.-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme.

More... »

AstraZeneca, Moderna Therapeutics to develop pioneering messenger RNA Therapeutics

Friday, March 22, 2013 10:51 AM

AstraZeneca, a global biopharmaceutical company, has formed an exclusive agreement with Moderna Therapeutics, a Cambridge-Mass.-based biopharmaceutical company, to discover, develop and commercialize pioneering messenger RNA therapeutics for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer.

More... »

AstraZeneca to establish strategic R&D centers, cut or relocate 4,100 workers

Monday, March 18, 2013 02:12 PM

Global biopharmaceutical company AstraZeneca announced plans to invest in strategic R&D centers in the U.K., the U.S. and Sweden to improve pipeline productivity and to establish the company as a global leader in biopharmaceutical innovation.

More... »

AcelRx appoints Adrian Adams to board

Tuesday, February 12, 2013 08:00 AM

AcelRx Pharmaceuticals, a specialty pharmaceutical company focused on acute and breakthrough pain, has appointed Adrian Adams, CEO and president of Auxilium Pharmaceuticals, to its board of directors as chairman of the board.  

More... »

$262M Pan-European drug discovery platform launched

Friday, February 8, 2013 10:48 AM

The European Lead Factory, a novel platform for innovative drug discovery, was launched Feb. 7 by an international consortium of 30 partners. The partnership, the first of its kind, is supported by the Innovative Medicines Initiative (IMI) and creates opportunities for the discovery of new medicines by providing public partners with an “industry-like” discovery platform to translate cutting-edge academic research into high-quality drug lead molecules on a scale and speed that was not possible previously.

More... »

AtheroNova names Shaw as new clinical affairs officer

Thursday, January 10, 2013 08:00 AM

AtheroNova, a biotech company focused on compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, has appointed Joan E. Shaw, MT (ASCP), SCC as senior director of clinical operations.

More... »